Kaneka Medical America (KMA) was established in 1997 and is a wholly owned subsidiary of Kaneka Americas Holdings, Inc. KMA, with main office located in New York, NY, is the exclusive distributor in the U.S. and Canada for the extracorporeal Lipoprotein Apheresis system, LIPOSORBER, manufactured by Kaneka Corporation. It is the only Lipoprotein Apheresis therapy approved by FDA for the following two patient populations: 1. Clinically diagnosed Familial Hypercholesterolemic patients with either documented CAD or PAD, if LDL-C > 100mg/dl -or- Lp(a) > 60 mg/dl and LDL-C > 100 mg/dl when diet and maximum tolerable combination lipid-lowering drug therapies have failed to achieve the established therapeutic targets per professional guidelines. 2. Adult and pediatric patients with nephrotic syndrome associated with primary FSGS when: Standard treatment options, including corticosteroids and /or calcineurin inhibitor treatments, are unsuccessful or not well tolerated and the patients GFR > 60 ml/min/1.73 m2 The patient is post renal transplantation